BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 8646820)

  • 1. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
    Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.
    Tateishi T; Watanabe M; Nakura H; Asoh M; Shirai H; Mizorogi Y; Kobayashi S; Thummel KE; Wilkinson GR
    Clin Pharmacol Ther; 2001 May; 69(5):333-9. PubMed ID: 11372001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
    Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
    Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
    Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
    Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
    Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
    Labroo RB; Paine MF; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
    Emoto C; Yamazaki H; Iketaki H; Yamasaki S; Satoh T; Shimizu R; Suzuki S; Shimada N; Nakajima M; Yokoi T
    Xenobiotica; 2001 May; 31(5):265-75. PubMed ID: 11491388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.
    Farkas D; Oleson LE; Zhao Y; Harmatz JS; Zinny MA; Court MH; Greenblatt DJ
    J Clin Pharmacol; 2007 Mar; 47(3):286-94. PubMed ID: 17322140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
    Andersen V; Pedersen N; Larsen NE; Sonne J; Larsen S
    Br J Clin Pharmacol; 2002 Aug; 54(2):120-4. PubMed ID: 12207630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
    Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
    Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.